{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:25:28Z","timestamp":1785173128929,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2001,10]]},"DOI":"10.1007\/s11926-996-0010-x","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T07:18:19Z","timestamp":1180768699000},"page":"399-403","source":"Crossref","is-referenced-by-count":14,"title":["Recent advances in the treatment of the seronegative spondyloarthropathies"],"prefix":"10.1007","volume":"3","author":[{"given":"Christopher T.","family":"Ritchlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Daikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","volume":"42","author":"DO Clegg","year":"1999","unstructured":"Clegg DO, Reda DJ, Abdellatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999, 42:2325\u20132329. This paper reanalyzed the results of a large, double-blind, placebocontrolled trial of sulfasalazinc (SSZ) 2 g\/day in the treatment of SpA. There was a significant improvement in peripheral joint manifestations in patients treated with SSZ compared with patients treated with placebo. However, there was no significant improvement in axial joint manifestations compared with placebo.","journal-title":"Arthritis Rheum"},{"key":"10_CR2","doi-asserted-by":"crossref","unstructured":"Jones G, Crotty M, Brooks P: Interventions for psoriatic arthritis. Cochrane Database of Systematic Reviews [computer file]. 2000, 2:CD000212.","DOI":"10.1002\/14651858.CD000212"},{"key":"10_CR3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00002281-199907000-00003","volume":"11","author":"J Sieper","year":"1999","unstructured":"Sieper J, Braun J: Reactive arthritis. Curr Opin Rheumatol 1999, 11:238\u2013243.","journal-title":"Curr Opin Rheumatol"},{"key":"10_CR4","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 1999, 340:1398\u20131405.","journal-title":"N Engl J Med"},{"key":"10_CR5","first-page":"1544","volume":"25","author":"C Ritchlin","year":"1998","unstructured":"Ritchlin C, Haas-Smith SA, Hicks D, et al.: Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25:1544\u20131552.","journal-title":"J Rheumatol"},{"key":"10_CR6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000, 356:385\u2013390. This paper is the only published double-blind, placebo-controlled trial of anti-TNFa therapy in the treatment of SpA. Compared with placebo, etanercept led to a rapid and significant improvement in peripheral joint manifestations, severity of skin disease, and markers of inflammation in patients with PsA. The drug was well-tolerated with no significant toxicity.","journal-title":"Lancet"},{"key":"10_CR7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.59.6.428","volume":"59","author":"F Bosch Van den","year":"2000","unstructured":"Van den Bosch F, Kruithof E, Baeten D, et al.: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor a (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000, 59:428\u2013433. This paper reports the results of a small, open pilot study of three infusions of infliximab in the treatment of long-standing SpA. Patients experienced a rapid and sustained improvement in peripheral and axial manifestations.","journal-title":"Ann Rheum Dis"},{"key":"10_CR8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","volume":"43","author":"J Brandt","year":"2000","unstructured":"Brandt J, Haibel H, Cornley D, et al.: Successful treatment of active ankylosing spondylitis with anti-tumor necrosis factor a monoclonal antibody infliximab. Arthritis Rheum 2000, 43:1346\u20131352. This paper reports the results of a small, open-pilot study of three infusions of infliximab in the treatment of AS. Patients experienced a rapid and sustained improvement in axial manifestations and markers of inflammation. In a select group of patients evaluated by MRI, spinal inflammation decreased after treatment.","journal-title":"Arthritis Rheum"},{"key":"10_CR9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253\u2013259.","journal-title":"N Engl J Med"},{"key":"10_CR10","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DMFM, St. Clair EW, et al.:Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594\u20131602.","journal-title":"N Engl J Med"},{"key":"10_CR11","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","volume":"343","author":"JM Bathon","year":"2000","unstructured":"Bathon JM, Martin RW, Fleischmann RM, et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586\u20131593.","journal-title":"N Engl J Med"},{"key":"10_CR12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s100670050027","volume":"19","author":"D Biasi","year":"2000","unstructured":"Biasi D, Carletto A, Caramaschi P, et al.: Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 2000, 19:114\u2013117. This paper reports the results of a small, open, 3-year trial of low dose methotrexate in the treatment of AS. Significant improvement in axial manifestations was noted at 3 years. No radiographic progression of ankylosis was observed.","journal-title":"Clin Rheumatol"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/030097400750002021","volume":"29","author":"PD Sampaio-Barros","year":"2000","unstructured":"Sampaio-Barros PD, Costallat LTL, Bertolo MB, Neto JFM, Samara AM: Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000, 29:160\u2013162.","journal-title":"Scand J Rheumatol"},{"key":"10_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-198600321-00006","volume":"32","author":"AJ Taggert","year":"1986","unstructured":"Taggert AJ, Neumann VC, Hill J, et al.: 5 Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulfasalazine in rheumatoid arthritis? Drugs 1986, 32:27\u201334.","journal-title":"Drugs"},{"key":"10_CR15","first-page":"285","volume":"13","author":"VC Neumann","year":"1986","unstructured":"Neumann VC, Taggert AJ, Le-Gallez P, et al.: A study to determine the active moiety of sulfasalazine in rheumatoid arthritis. J Rheumatol 1986, 13:285\u2013287.","journal-title":"J Rheumatol"},{"key":"10_CR16","first-page":"612","volume":"21","author":"F Imai","year":"1994","unstructured":"Imai F, Suzuki T, Ishibashi T, Tanaka M, Akiyama Y: Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis. J Rheumatol 1994, 21:612\u2013615.","journal-title":"J Rheumatol"},{"key":"10_CR17","first-page":"892","volume":"2","author":"AK Azad Kahn","year":"1977","unstructured":"Azad Kahn AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet 1977, 2:892\u2013899.","journal-title":"Lancet"},{"key":"10_CR18","first-page":"714","volume":"27","author":"GTD Thomson","year":"2000","unstructured":"Thomson GTD, Thomson BRJ, Thomson KS, Ducharme JS:Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol 2000, 27:714\u2013718.","journal-title":"J Rheumatol"},{"key":"10_CR19","first-page":"723","volume":"27","author":"BJ Dekker-Saeys","year":"2000","unstructured":"Dekker-Saeys BJ, Dijkmans BAC, Tytgat GNJ: Treatment of spondyloarthropathy with 5-aminosalicyclic acid (mesalamine): an open trial. J Rheumatol 2000, 27:723\u2013726.","journal-title":"J Rheumatol"},{"key":"10_CR20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.59.7.565","volume":"59","author":"T Yli-Kerttula","year":"2000","unstructured":"Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al.: Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 2000, 59:565\u2013570. This double-blind placebo-controlled trial of 71 patients with acute ReA treated with ciprofloxacin for 3 months demonstrated no benefit over placebo. Both groups tended to improve over 12 months.","journal-title":"Ann Rheum Dis"},{"key":"10_CR21","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/1529-0131(199907)42:7<1386::AID-ANR12>3.0.CO;2-E","volume":"42","author":"J Sieper","year":"1999","unstructured":"Sieper J, Fendler C, Laitko S, et al.: No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double blind, randomized, placebo-controlled study. Arthritis Rheum 1999, 42:1386\u20131396.","journal-title":"Arthritis Rheum"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-996-0010-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-996-0010-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-996-0010-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:50:13Z","timestamp":1559422213000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-996-0010-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s11926-996-0010-x","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10]]}}}